Back to Archived Journals » Vaccine: Development and Therapy » Volume 5

Current and future prophylactic vaccines for hepatitis C virus

Authors Dunlop J, Owsianka A, Cowton V, Patel A

Received 27 February 2015

Accepted for publication 12 May 2015

Published 11 August 2015 Volume 2015:5 Pages 31—44

DOI https://doi.org/10.2147/VDT.S48437

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 6

Editor who approved publication: Professor Don Diamond


James I Dunlop, Anna M Owsianka, Vanessa M Cowton, Arvind H Patel

MRC-University of Glasgow Centre for Virus Research, Glasgow, Scotland, UK

Abstract: The development of a vaccine is necessary to combat the global hepatitis C virus (HCV) epidemic. The key to the development of a prophylactic vaccine is understanding the immune response in those who spontaneously resolve HCV infections versus those who develop chronic disease. Several promising vaccine candidates based on the use of viral vectors are currently in Phase I and Phase II clinical trials. The recently solved structures of the E2 glycoprotein have greatly aided epitope- and antibody-based vaccine design.

Keywords: antibody, E1E2 glycoproteins, epitope, HCV, neutralizing antibody, viral vector

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]